LifeSci Capital analyst Rahul Rakhit maintained a Hold rating on Better Therapeutics, Inc. (BTTX – Research Report) today. The company’s shares opened today at $0.69.
Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Akili, and Orchestra BioMed Holdings. According to TipRanks, Rakhit has an average return of -52.9% and a 5.13% success rate on recommended stocks.
Currently, the analyst consensus on Better Therapeutics, Inc. is a Moderate Buy with an average price target of $9.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.23 and a one-year low of $0.59. Currently, Better Therapeutics, Inc. has an average volume of 32.92K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mountain Crest Acquisition Corp II is a blank check company.
Read More on BTTX:
